Antiviral Efficacy and Host Immune Response Induction with SB 9200, an Oral Prodrug of the Dinucleotide SB 9000, in Combination with Entecavir in the Woodchuck Model of Chronic Hepatitis B

Korolowicz, Kyle E.; Balarezo, Maria; Iyer, Radhakrishnan P.; Padmanabhan, Seetharamaiyer; Cleary, Dillon; Gimi, Rayomand; Sheri, A.; Suresh, Manasa; Yon, Changsuek; Tucker, Robin D.; Afdhal, Nezam H.; Menne, Stephan

doi:10.1016/s0168-8278(16)01111-9

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pretreatment with SB 9200 to induce a host immune response followed by ETV in woodchucks was found to have a significant reduction in viral DNA, RNA, and antigens compared to viral reduction with ETV followed by immune modulation. A Phase II clinical trial of SB 9200 alone and in combination with a nucleoside to treat chronic HBV is therefore planned [ 96 ]. Therapeutic vaccines …”

Section: New Nasmentioning

confidence: 99%

Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?

et al. 2017

View full text Add to dashboard Cite

BackgroundHepatitis B virus (HBV) chronic infection affects up to 240 million people in the world and it is a common cause of cirrhosis and hepatocellular carcinoma (HCC). HBV covalently closed circular DNA (cccDNA) plays an essential role in HBV persistence and replication. Current pharmacological treatment with nucleos(t)ide analogues (NA) may suppress HBV replication with little or no impact on cccDNA, hence lifelong treatment is required in the vast majority of patients. Clearances of intrahepatic cccDNA and/or HBsAg are critical endpoints for future antiviral therapy in chronic HBV. Recent promising developments targeting different molecular HBV life cycle steps are being pre-clinically tested or have moved forward in early clinical trials.MethodsWe review the current state of the art of these pharmacological developments, mainly focusing on efficacy and safety results, which are expected to lay the ground for future HBV eradication. An inclusive literature search on new treatments of HBV using the following electronic databases: Pubmed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts and abstracts published over the last 12 years, from 2005 to March 2011 were reviewed for relevance and reference lists were crosschecked for additional applicable studies regarding new HBV antiviral treatment.ResultsHBV entry inhibitors, HBV core inhibitors, HBV cccDNA transcripts RNA interference, HBV cell apoptosis inducers, HBV RNA, viral proteins and DNA knock down agents, HBV release inhibitors, anti-sense nucleosides, exogenous interferon stimulation, interferon response stimulation and HBV therapeutic vaccines were reviewed.ConclusionThis review will provide readers with an updated vision of current and foreseeable therapeutic developments in chronic hepatitis B.

show abstract

Section: New Nasmentioning

confidence: 99%